Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 2/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14768567 | 0.88 | SYK (0.57) | SYKPPARACTSSPPARGATM | |
| SCHEMBL4904600 | 0.88 | SYK (0.57) | SYKPPARACTSSPPARGATM | |
| SCHEMBL34470799 | 0.87 | SYK (0.56) | SYKPPARACTSSPPARGATM | |
| SCHEMBL21156218 | 0.86 | SYK (0.55) | SYKPPARACTSSPPARGATM | |
| SCHEMBL34471377 | 0.86 | SYK (0.55) | SYKPPARACTSSPPARGATM | |
| SCHEMBL25602602 | 0.85 | SYK (0.55) | SYKPPARACTSSPPARGATM | |
| SCHEMBL2436732 | 0.85 | SYK (0.54) | SYKPPARACTSSPPARGATM | |
| SCHEMBL24049692 | 0.84 | SYK (0.53) | SYKPPARACTSSPPARGATM | |
| SCHEMBL18921977 | 0.82 | SYK (0.52) | SYKPPARACTSSPPARGATM | |
| SCHEMBL24837876 | 0.82 | SYK (0.52) | SYKPPARACTSSPPARGATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859812-B2 | Compound reagents and method for synthesizing enantiomerically enriched amino acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859812-B2 | Compound reagents and method for synthesizing enantiomerically enriched amino acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130066109-A1 | COMPOUNDS AND RELATED METHODS OF USE | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066109-A1 | COMPOUNDS AND RELATED METHODS OF USE | BCAT2, BCAT1, AADAT | SYK 4024/4885PPARA 2907/4885CTSS 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.